Affimed N.V (NASDAQ: AFMD)’s stock price has soared by 27.15 in relation to previous closing price of 0.62. Nevertheless, the company has seen a gain of 38.73% in its stock price over the last five trading days. globenewswire.com reported 2025-03-25 that MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has been accepted for presentation as a poster at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 25-30, 2025 in Chicago, Illinois.
Is It Worth Investing in Affimed N.V (NASDAQ: AFMD) Right Now?
AFMD has 36-month beta value of 2.14. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AFMD is 13.02M, and currently, short sellers hold a 4.54% ratio of that float. The average trading volume of AFMD on April 15, 2025 was 126.50K shares.
AFMD’s Market Performance
AFMD stock saw a decrease of 38.73% in the past week, with a monthly decline of -10.12% and a quarterly a decrease of -29.38%. The volatility ratio for the week is 15.29%, and the volatility levels for the last 30 days are 10.69% for Affimed N.V (AFMD). The simple moving average for the past 20 days is 6.23% for AFMD’s stock, with a -70.69% simple moving average for the past 200 days.
Analysts’ Opinion of AFMD
Many brokerage firms have already submitted their reports for AFMD stocks, with H.C. Wainwright repeating the rating for AFMD by listing it as a “Buy.” The predicted price for AFMD in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 12, 2022 of the previous year 2022.
Stifel, on the other hand, stated in their research note that they expect to see AFMD reach a price target of $2, previously predicting the price at $9. The rating they have provided for AFMD stocks is “Hold” according to the report published on October 10th, 2022.
AFMD Trading at -11.90% from the 50-Day Moving Average
After a stumble in the market that brought AFMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.16% of loss for the given period.
Volatility was left at 10.69%, however, over the last 30 days, the volatility rate increased by 15.29%, as shares sank -12.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.69% lower at present.
During the last 5 trading sessions, AFMD rose by +38.73%, which changed the moving average for the period of 200-days by -85.80% in comparison to the 20-day moving average, which settled at $0.7446. In addition, Affimed N.V saw -33.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AFMD
Current profitability levels for the company are sitting at:
- -80.05 for the present operating margin
- 1.0 for the gross margin
The net margin for Affimed N.V stands at -79.78. The total capital return value is set at -3.03. Equity return is now at value -151.46, with -88.07 for asset returns.
Based on Affimed N.V (AFMD), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at -5.97. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is -51.7.
Currently, EBITDA for the company is -102.38 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 18.37. The receivables turnover for the company is 0.19for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.93.
Conclusion
To put it simply, Affimed N.V (AFMD) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
